Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of obeticholic acid in pediatric biliary atresia
2014-004693-42Phase 2Unknown
- Sponsor
- Intercept Pharmaceuticals
- Start
- Dec 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obeticholic acid in biliary atresia, sponsored by Intercept Pharmaceuticals. Primary endpoint: Safety and tolerability of obeticholic acid. Status: unknown.
02
Drugs
obeticholic acid
03
Conditions
biliary atresia
Beyond the preview
Go deeper on 2014-004693-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004693-42.